Skip to content

Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a long-term lung condition in which the airways become inflamed and narrowed, making it progressively harder to breathe. It covers two overlapping patterns: emphysema, where the air sacs lose their elasticity, and chronic bronchitis, where the airway lining produces excess mucus. COPD does not reverse, but it can be stabilised and its daily impact significantly reduced.

Medicines used to treat Chronic Obstructive Pulmonary Disease

Ventolin Inhaler

Salbutamol

100mcg

Ventolin Inhaler is salbutamol 100mcg as a pressurised inhalation solution for asthma and COPD, a fast-acting beta2 agonist.

FromUS$20.40/ inhalerView

Advair Diskus

Salmeterol, Fluticasone

100/50 · 250/50 · 500/50mcg

Salmeterol with fluticasone inhalation powder in three strengths, used in the management of asthma and COPD. A long-acting beta2-agonist with a corticosteroid.

FromUS$106.55/ inhalerView

Seroflo Inhaler

Fluticasone, Salmeterol

25/125 · 25/250mcg

Seroflo Inhaler carries fluticasone with salmeterol as a pressurised suspension for asthma and COPD, a corticosteroid with a long-acting agonist.

FromUS$34.00/ inhalerView

Key points

  • The disease spans two overlapping patterns, loss of elasticity in the air sacs and excess mucus production in the airway lining.
  • Smoke from indoor biomass cooking, such as wood or coal, adds a substantial risk beyond tobacco, particularly affecting rural women.
  • Early breathlessness is often written off as a smoker’s cough or simple ageing, pushing diagnosis back for years.
  • Structured exercise paired with breathing technique training lifts daily function further than medicines can achieve alone.

What drives COPD

Tobacco smoking is the dominant cause globally, but prolonged exposure to biomass cooking smoke, from wood, coal, and crop residue burned indoors, is a major independent risk factor, particularly among women in rural areas. Air quality in dense urban centres adds further burden. Occupational dust and fume exposure in manufacturing and construction also contribute.

Recognising the pattern of symptoms

COPD typically builds slowly over years. A morning cough producing clear or yellowish mucus, gradually worsening breathlessness on exertion, and a sensation of chest tightness are the hallmark features. Wheezing is common. Many people dismiss early symptoms as a “smoker’s cough” or normal ageing, which delays diagnosis by a decade or more. Acute flare-ups, called exacerbations, produce a sudden worsening of breathlessness, increased mucus, and sometimes fever; these need prompt attention as they accelerate lung decline.

How COPD is managed

Treatment aims to open the airways, reduce inflammation, and prevent exacerbations. Short-acting bronchodilators such as salbutamol relieve breathlessness quickly during a flare. Long-acting bronchodilators like salmeterol and tiotropium provide sustained airway opening throughout the day. Inhaled corticosteroids, budesonide and fluticasone, reduce airway inflammation and are often combined with a long-acting bronchodilator in a single inhaler. Theophylline tablets remain widely used where inhaler access or cost is a barrier. Pulmonary rehabilitation, structured exercise and breathing training, improves function and quality of life beyond what medicines alone can achieve. Stopping smoking at any stage slows progression.

Seek urgent care if breathlessness becomes severe at rest, lips or fingertips turn bluish, or a flare does not improve within a day or two of starting usual treatment. Browse the full respiratory health range for available options.

Further reading

Last updated